Abstract:To the Editor: Hereditary hemorrhagic telangiectasia (HHT) is an inherited disorder characterized by vascular ectasias in different organs, including gastrointestinal (GI) tract telangiectases. Officially classified as a rare disorder, the incidence in the United States is estimated to be 10 to 20 per 100,000 people with over 50,000 affected Americans. GI bleeding affects 25% to 30% of patients with HHT, usually over the age of 40 years. Of these approximately 25% will have significant GI bleeding requiring multiple blood transfusions often weekly for many years. There have been several cases of HHT patients requiring over 100U of blood during their lifetime from GI blood loss. There is very little data to guide physicians in treating this very problematic group of patients. A gastroenterologist’s initial reaction when GI telangiectases are encountered in a patient with anemia and GI bleeding is to attempt to cauterize them. This can be particularly problematic in HHT patients where the telangiectases are multiple and extend distally beyond the reach of a standard endoscope. Our group published the largest case series to date in 2003, with 40 patients with HHT and GI bleeding who were evaluated for response to medical therapy. Some patients responded extraordinarily well to hormonal therapy whereas others did not. The literature on estrogen therapy in HHT patients with bleeding GI lesions is very sparse with a few case reports and a single randomized trial studying the long-term effect of hormonal therapy on bleeding GI vascular malformations. In a study published in 1993, 7 of 8 patients with HHT had no evidence of bleeding while taking ethinylestradiol 0.05mg and norethisterone 1mg (Ovcon 50) for 6 months versus placebo and were, therefore, considered treatment successes. Because there is insufficient evidence to recommend systemic therapy or local endoscopic therapy for patients with HHT and GI bleeding, our group undertook a pilot study to evaluate ethinylestradiol 0.05mg and norethisterone 1mg (Ovcon 50) versus local endoscopic argon plasma coagulation therapy in patients with HHT and GI bleeding. We report the first patient who entered the trial on the hormonal arm and completed 12 months of therapy. This study was approved by the Yale University School of Medicine Human Investigation Committee. The patient is a 51-year-old woman with HHT and transfusiondependent GI bleeding. During the 5 years before study entry, she had required more than 150U of packed red blood cell transfusions and the year before study entry, she had required 79U of packed red blood cell transfusions. She was hepatitis C virus-positive and had been treated with interferon 10 years ago. She had 2 pulmonary arteriovenous malformations that had been closed just before study entry. She was receiving intravenous iron 3 times per week with her hematocrit ranging from 17% to 31%. An enteroscopy revealed 8 telangiectases in her stomach; 53 in her duodenum; and 79 in the first 60 cm of her jejunum. A colonoscopy revealed 10 telangiectases scattered throughout her colon. She was randomized to receive daily oral ethinylestradiol 0.050mg and norethindrone 1.0mg (Ovcon 50) for 1 year. Over the next 4 months, her transfusion requirements slowly and steadily markedly decreased so that she required only 10U over this time. Her last transfusion was 4 months after starting combination estrogen and progesterone therapy and since then she has maintained a hematocrit over 35%. She has now completed 14 months of hormonal therapy and has had no adverse effects. She has remained on intravenous iron, but decreased her dose to twice weekly. This case report illustrates that patients with HHT and severe anemia owing to GI telangiectases should be considered for combination estrogen and progesterone therapy as second line therapy if they are unable to maintain an adequate hematocrit level on oral and/or intravenous iron therapy.

Sacrificial polymer thin-film template with tunability to construct high-density Au nanoparticle arrays and their refractive index sensing.

Population structure and dynamics of an evergreen shade herb, Ainsliaea apiculata (Asteraceae), with special reference to herbivore effects

Hormonal therapy for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.

Effect of dendrobium mixture in alleviating diabetic cognitive impairment associated with regulating gut microbiota

Effect and Mechanism of Auricularia Auriculajudae Polysaccharide in Hippocampus of Streptozotocin‐induced Diabetic Cognitive Impairment Rats

DL-3-n-butylphthalide ameliorates diabetes-associated cognitive decline by enhancing PI3K/Akt signaling and suppressing oxidative stress

Transformation of vegetative cells of Bacillus thuringiensis by plasmid DNA

Error diagnosis and classi fication of errors in two Hebrew state-ofthe-art automatic speech recognition systems

Compound Danshen Dripping Pills Moderate Intestinal Flora and the TLR4/MyD88/NF-κB Signaling Pathway in Alleviating Cognitive Dysfunction in Type 2 Diabetic KK-Ay Mice

Resolvin E1 ameliorates diabetes‐related cognitive impairment via ChemR23

Dapagliflozin improves diabetic cognitive impairment via indirectly modulating the mitochondria homeostasis of hippocampus in diabetic mice

Restoration, not preservation, of general surgery residency.

An Address on the Science of Clinical Medicine

Huang-Lian-Jie-Du decoction attenuates cognitive dysfunction of rats with type 2 diabetes by regulating autophagy and NLRP3 inflammasome activation

Radix polygoni multiflori protects against hippocampal neuronal apoptosis in diabetic encephalopathy by inhibiting the HDAC4/JNK pathway

2-Hydroxyisobutyric acid targeted binding to MT-ND3 boosts mitochondrial respiratory chain homeostasis in hippocampus to rescue diabetic cognitive impairment

Protective Effects of 2-Dodecyl-6-Methoxycyclohexa-2,5 -Diene-1,4-Dione Isolated from Averrhoa Carambola L. (Oxalidaceae) Roots on High-Fat Diet-Induced Obesity and Insulin Resistance in Mice

Danggui Buxue decoction ameliorates mitochondrial biogenesis and cognitive deficits through upregulating histone H4 lysine 12 acetylation in APP/PS1 mice

2-Dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione, isolated from the root of Averrhoa carambola L., protects against diabetic kidney disease by inhibiting TLR4/TGFβ signaling pathway

Forsythoside B ameliorates diabetic cognitive dysfunction by inhibiting hippocampal neuroinflammation and reducing synaptic dysfunction in ovariectomized mice

2-Dodecyl-6-Methoxycyclohexa-2, 5-Diene-1, 4-Dione isolated from Averrhoa carambola L. root inhibits high glucose-induced EMT in HK-2 cells through targeting the regulation of miR-21–5p/Smad7 signaling pathway